Please login to the form below

Not currently logged in
Email:
Password:

Vyvanse

This page shows the latest Vyvanse news and features for those working in and with pharma, biotech and healthcare.

Shire separates out neuroscience as it considers its future

Shire separates out neuroscience as it considers its future

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the

Latest news

More from news
Approximately 3 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    However, with attention deficit hyperactivity disease (ADHD) treatment Vyvanse accounting for more than a quarter of its revenues it's clear that, even after its combination with Baxalta is completed, neuroscience ... Meanwhile, the US also has the

  • Pharma deals during June 2014 Pharma deals during June 2014

    study with Vyvanse.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics